» Articles » PMID: 36279362

AgeMTPT, a Catalyst for Peptide N-Terminal Modification

Overview
Journal ACS Synth Biol
Date 2022 Oct 24
PMID 36279362
Authors
Affiliations
Soon will be listed here.
Abstract

A key goal of synthetic biology is to enable designed modification of peptides and proteins, both in vivo and in vitro. N- and C-Terminal modification enzymes are crucial in this regard, but there are a few enzymatic options to protect peptide termini. AgeMTPT protects the N-terminus of short peptides with isoprene and the C-terminus as a methyl ester, but its substrate scope is unknown, limiting its application. Here, we investigate the substrate selectivity of the prenyltransferase domain, revealing a requirement for N-terminal aromatic amino acids, but with tolerance for diverse uncharged amino acids in the remaining positions. To demonstrate the potential of the enzyme, substrate selectivity data were used in the enzymatic modification of leu-enkephalin at the critical N-terminal residue. AgeMTPT active site mutagenesis led to an enzyme with expanded substrate scope, including the reverse geranylation of the N-termini of peptides. These data reveal potential applications of enzymatic peptide protection in synthetic biology.

Citing Articles

Promiscuous Enzymes for Residue-Specific Peptide and Protein Late-Stage Functionalization.

Alexander A, Elshahawi S Chembiochem. 2023; 24(17):e202300372.

PMID: 37338668 PMC: 10496146. DOI: 10.1002/cbic.202300372.

References
1.
Gu W, Schmidt E . Three Principles of Diversity-Generating Biosynthesis. Acc Chem Res. 2017; 50(10):2569-2576. PMC: 6433375. DOI: 10.1021/acs.accounts.7b00330. View

2.
Purushothaman M, Sarkar S, Morita M, Gugger M, Schmidt E, Morinaka B . Genome-Mining-Based Discovery of the Cyclic Peptide Tolypamide and TolF, a Ser/Thr Forward O-Prenyltransferase. Angew Chem Int Ed Engl. 2021; 60(15):8460-8465. PMC: 8011950. DOI: 10.1002/anie.202015975. View

3.
Roy A, Kucukural A, Zhang Y . I-TASSER: a unified platform for automated protein structure and function prediction. Nat Protoc. 2010; 5(4):725-38. PMC: 2849174. DOI: 10.1038/nprot.2010.5. View

4.
Arnison P, Bibb M, Bierbaum G, Bowers A, Bugni T, Bulaj G . Ribosomally synthesized and post-translationally modified peptide natural products: overview and recommendations for a universal nomenclature. Nat Prod Rep. 2012; 30(1):108-60. PMC: 3954855. DOI: 10.1039/c2np20085f. View

5.
Przewlocki R, Labuz D, Mika J, Przewlocka B, Tomboly C, Toth G . Pain inhibition by endomorphins. Ann N Y Acad Sci. 2000; 897:154-64. DOI: 10.1111/j.1749-6632.1999.tb07887.x. View